# Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

Source: https://onco.cc/trials/nct07155629/  
OnCo record `nct07155629` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by Helsinki University Central Hospital, not yet recruiting.

## Summary

Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT07155629 by Helsinki University Central Hospital, with a registry enrolment figure of 381 participants, started 2025-09-01 and due to reach its primary completion in 2030-08-31. Interventions recorded: mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: Overall Survival. Pancreatic eligibility wording from the registry: "* Resectable left pancreatic cancer according to NCCN criteria". Sites: Finland. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: LEFT-PANC
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07155629
- Phase: 3
- Setting: Neoadjuvant Treatment vs Upfront Surgery for Left Sided Pancreatic Cancer (LEFT-PANC) - a Study Protocol for a Prospective Randomized Multicenter Trial
- Sponsor: Helsinki University Central Hospital
- Enrolled: 381

## Sources

- ClinicalTrials.gov NCT07155629: https://clinicaltrials.gov/study/NCT07155629

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07155629.json